How Will Neurotech Leverage FDA Rare Disease Status to Advance NTI164?

middle.news 9:06am on Friday 30th of January, 2026 AEDT • Healthcare Read Story

How Will Neurotech Leverage FDA Rare Disease Status to Advance NTI164?

9:06am on Friday 30th of January, 2026 AEDT Key Points FDA grants Rare Pediatric Disease Designation for NTI164 in Rett syndrome Positive clinical and mechanistic data published for NTI164 in PANS Raised approximately $4 million via placement plus $4.73 million R&D tax refund Board participation in placement signals strong internal confidence Read Story

middle. Tap to Read Tap the card to read the full analysis about NEUROTECH INTERNATIONAL (ASX:NTI) OPEN ARTICLE